Jupiter Topco LLC Invests $450.14 Million in United Therapeutics Corporation $UTHR

Jupiter Topco LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, Holdings Channel reports. The fund purchased 831,129 shares of the biotechnology company’s stock, valued at approximately $450,140,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of UTHR. Arjuna Capital boosted its stake in shares of United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC lifted its holdings in United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after buying an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC boosted its position in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 24 shares during the period. Meeder Advisory Services Inc. grew its stake in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance grew its stake in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 27 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Trading Up 1.1%

Shares of NASDAQ:UTHR opened at $518.53 on Wednesday. The company has a market capitalization of $22.24 billion, a PE ratio of 18.55, a P/E/G ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The firm has a 50 day simple moving average of $531.75 and a 200-day simple moving average of $538.30.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $6.41 EPS. As a group, equities research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,311,581.28. This represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total transaction of $5,185,385.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,113,210.79. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 434,075 shares of company stock worth $233,340,010. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on UTHR shares. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Bank of America cut their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 price objective on United Therapeutics in a research note on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.